ImportInfo Newsletter July 2023

New Supply Offers: July 2023

TFO Canada received 25 new supply offers in these categories:

7- Food products and beverages (Inc. seafood)
7 – Fashion Accessories
5 – Clothing (not Inc. footwear)
2 – Home Décor, Giftware and Crafts
2 – Office and Other Professional Supplies
1 – Personal Care, pharmaceuticals and natural health products
1 – Automotive and Accessories

Updated Canadian Customs Tariff list (T-2023-6) effective July 12, 2023.

On June 22, 2023, Bill C-47 was enacted, introducing amendments to the Food and Drugs Act (FDA) to extend existing provisions of the FDA to now apply equally to natural health products.

The key provisions, which take immediate effect, include:

Information Disclosure – Health Canada can now order individuals or entities to provide information to determine if they deem an NHP product presents a serious risk of injury to human health.
Labelling and Packaging Modifications – Health Canada now has the authority to require a label change or package modification if they deem an NHP product presents a serious risk of injury to human health
Recall Authority – Health Canada now has the ability to order a recall of NHPs that present a serious or imminent risk of injury to human health.
Increased Fines and Penalties – Health Canada can now impose higher fines and penalties to deter non-compliance with NHP regulations. The amendments include fines of up to $5,000,000.00 CAD or 2 years in prison as a penalty for failing to comply with the provisions.
Incorporation by Reference- This provision grants Health Canada the ability to incorporate external documents, standards, or guidelines by reference, streamlining the regulatory process and aligning with recognized best practices.
Prohibition of False or Misleading Statements – False or misleading statements, or providing inaccurate information to the Minister is now expressly prohibited.
Confidential Business Information – This provision grants Health Canada the authority to disclose confidential business information if they deem that an NHP may present a serious health or injury risk, or for the protection and promotion of human health.

If you import, sell, distribute, package, label or manufacture NHPs in Canada please review the therapeutic product provisions and the NHPR to ensure your products are in compliance.